1 / 16

Purine and uric acid metabolism disorders

Purine and uric acid metabolism disorders. Clinical b iochemistry 200 8 (J.S.). Synthesis of purine de novo : . PRPP-amidotransferase. Methenyl-H 4 folate C 1. Glycine. Rate-limiting step Allosteric inhibition by the end-products - AMP, GMP. AMP GMP. Glutamine –NH 2.

arturoh
Télécharger la présentation

Purine and uric acid metabolism disorders

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Purine and uric acid metabolism disorders Clinical biochemistry 2008 (J.S.)

  2. Synthesis of purine de novo : PRPP-amidotransferase Methenyl-H4folate C1 Glycine Rate-limiting step Allosteric inhibition by the end-products - AMP, GMP AMP GMP Glutamine –NH2 H2O Inosine-5´-phosphate´ Formyl-H4folate C1 Aspartate –NH2

  3. Purine salvage pathways(salvage reactions, reutilization of purines): Adenosine + ATP  adenosine monophosphate + ADP Adenosinekinase Purine (hypoxanthine, guanine, adenine) + PRPP   purine nucleotide monophosphate + PPi Phosphoribosyl transferasesHGPRT a APRT Salvage pathways occur in considerable extent in tissues with low synthesis of purines de novo,namely in CNS, bone marrow, and leukocytes. At low concentration of purine nucleotide catabolism end-products, reutilization of purine bases through salvage reactions in preferred over the purine degradation..

  4. Purine salvage pathways(salvage reactions, reutilization of purines): AMP GMP Adenosine Guanosine Ado kinase HGPRT APRT Adenine Guanine PRPP PRPP ATP IMP XMP Inosine Xantosine Hypoxantine Xantine Urate PRPP HGPRT

  5. Purine nucleotide degradation: AMP GMP Guanosine Adenosine (Adenine) Guanine IMP XMP Inosine Xanthosine Hypoxanthine Xanthine Xanthine dehydrogenase / oxidase URIC ACID Allantoin (non-enzymatic reaction initiated by •OH) CO2 In humans and uricotelic animals urate oxidase that catalyzes the oxidative splitting of urate to allantoin is absent !

  6. Xanthine oxidase Xanthine oxidase Hypoxanthine Xanthine Uric acid (6-hydroxypurine)(2,6-dihydroxypurine)(2,6,8-trihydroxypurine) Xanthine oxidase oxidizes hypoxanthine to xanthine and this same enzyme oxidizes xanthine to uric acid. The lactam forms of those compounds are shown: Uric acid is the final metabolic product of purine catabolism in humans and other primates (also in uricotelic animals - birds and land-dwelling reptiles), and is excreted in the urine. Other organisms, incl. most mammals, metabolize urate to allantoin or other simpler forms.

  7. Xanthine oxidase ((XO) is a molybdenum- and iron-containing flavoprotein, which may exist in two forms – D-form and O-form. Under physiological conditions, the D-formcatalyses the oxidation (hydroxylation) as a dehydrogenase, the acceptor of electrons is NAD+. XO – form D NADH+H+ NAD+ H2O In tissue hypoxia, the D-form is transformed into the O-form by the proteolytic splitting of 20 amino acyl residues. The O-form is a oxygenase, the acceptor of electrons is dioxygen. Then the reaction produces superoxide anion-radicals which dismutase into hydrogen peroxide by the action of SOD (the cause of so-called "reperfusion injury" after the restoration of a sufficient oxygen supply to the ischaemic tissue). XO – form O Hypoxanthine / Xanthine Urate ・O2– Hypoxanthine / Xanthine O2 H2O Urate H2O2

  8. Allopurinol inhibition of xanthine oxidase Hyperuricacidaemias and gouty syndromes are usually treated with allopurinol, a "suicide" inhibitor of xanthine oxidase. Instead of urate, the final products of purine catabolism are then hypoxanthine and xanthine, which are more soluble and thus more easily excreted into the urine. Allopurinol is oxidized by xanthine oxidase to 2-hydroxyallopurinol (alloxanthine) that remains bound to the molybdenum atom of the enzyme, thereby inactivating it. Allopurinol Alloxanthine is released from the enzyme with the half-life of about 5 h. Allopurinol thus acts as a uricostatic (Milurit, Urosin, etc.). After allopurinol, oxidation to uric acid is inhibited.

  9. Uric acid(2,6,8-trihydroxypurine) is a very weak diprotic acid. The pKa1 equals 5,75, therefore the predominant form of uric acid in body fluids is the monovalent hydrogen urate anion. Unfortunately, uric acid and its urate salts have a low solubility in water. The average serum concentrations in humans (the upper limit ~ 400 mol/l) is close to the solubility limit, above which the precipitation of needle-shaped monosodium urate crystals may begin. Urate crystals then occur frequently as deposites in the soft tissues, particularly in interstitium of the kidney and in joints, or in renal stones. On the other hand, an increase in urate concentration in primates has a markedly beneficial action. Urate is a highly effective antioxidant - a scavenger of reactive oxygen species which is about as effective as ascorbate taken in the diet. In the reaction with oxygen radicals, urate is changed into the radical that is non-enzymatically (spontaneously) transformed into allantoin. Primates thus excrete small amounts of allantoin proportionally to their exposure to oxidative stress, although they lack the urate oxidase. Lactam form Lactim form Mr = 168

  10. Elimination of urate • The total amount of uric acid in a normal man is approximately 7 mmol • (1.2 g), about 2 mmol being produced each day and eliminated. • About 20 % of the eliminated amount is excreted in the bile and is partially degraded in the GIT by intestinal microflora to CO2 and NH3. • Approximately 80 % of urate is excreted in the urine: • – filtrated freely by the glomerulus, • – over 90 % of filtrated urate reabsorbed in proximal tubules, • – tubular secretion, the mechanism is the same as that for other organic acids (and so the urate excretion diminished competitively at high secretion of lactate, acetoacetate, 3-hydroxybutyrate, and during therapy with thiazide diuretics or acetylsalicylate), • – postsecretion reabsorption in the distal parts of nephron that is inhibited (urate excretion increased) by uricosurics as, e.g. • probenecid (Benemid) or NSAD with exception to salicylates. • Plasma clearance of urate is rather low, about 0,1 - 0,2 ml / s, i.e. • the excretion fraction F/Eof urate is only 10 % on the average.

  11. Investigation of purine metabolism Basal: Serum uric acid – reference range 200 - 420 mol/l in men, 140 - 360 mol/l in women. Urinary excretion without purine restriction 1.5 – 4.4 mmol/d (250 - 750 mg/d) low-purine diet < 2.5 mmol/d (< 420 mg/d) Kaufman's index - urine ratio urate/creatinine 0,2 - 0,4 (mmol/mmol) In hyperuricaemia: Serum uric acid after a purine load Plasma urate clearance and excretion fraction (to exclude a renal disorder) Search for dyslipidaemia, decreased glucose tolerance, ischaemic heart disease, test for the liver functions. Special tests: Urinary excretion of xanthine, blood activities of HGPRT and adenine deaminase.

  12. Hyperuricaemia Mild latent hyperuricaemia without clinical symptoms occurs in approximately 4 - 10 % of healthy individuals. (Is it the sign of good adaptation to an increased production of reactive oxygen species ?) Defects in purine metabolism Inborn gouty syndromes Gout (primary gout) is a metabolic disease caused by accumulation of excess urate in body fluids due to the miscontrol of endogenous purine de novo synthesis supported by high intake of purines in the diet. Gout predominantly affects males, the peak incidence between the fourth and sixth decades. It is rare in adolescents, extremely rare in women. The crystals of monosodium urate are deposited in joints (painful arthritis), around them, or in other tissues, particularly in kidneys (may result in urate urolithiasis or renal failure). Asymptomatic stage – characteristic acute gout attacks (big toe is the typical site of the first attack) – progression to chronic gout (joint swelling and destruction, tophi in the ears and around joints).

  13. Lesch-Nyhan syndromeis a rare nearly complete deficit in hypoxanthine-guanine phosphoribosyl transferase (HGPRT, see scavenger pathways of nucleotide synthesis), that stimulates an overproduction of purines. Children with this disease exhibit mental retardation, spasticity, compulsive self-destructive behaviour (biting their fingers and lips) and aggression toward others. An incomplete deficit in HGPRT leads in adults only to the formation of renal stones followed by the gouty arthritis years later (Kelley-Seegmiller syndrome). Familial hyperuricaemic nephropathy of juvenilesis a serious defect of urate renal excretion of young persons that leads progressively to the renal failure. Immunodeficiency syndromes The autosomal recessive form of severe combined immunodeficiency syndrome (SCIDS) has its cause in approximately 50 % of patients in a genetic deficiency of adenosine deaminase, which is oft associated with defects of 5´-nucleotidase and nucleoside phosphorylase, too. All these enzymes take part in the purine salvage pathway.

  14. "Secondary" hyperuricaemia and/or gout may have its cause in – an intensified desintegration of cells, e.g. in myelo- and lymphoproliferative diseases, during the cytostatic cancer chemotherapy, in hypercatabolic states (prolonged starvation, chronic alcoholism, high doses of corticosteroids), – a decreased renal excretion of urate in renal diseases or due to the side-effect of some kind of diuretics (thiazides, also furosemide). Hyperuricacidaemias and gouty syndromes are usually treated with allopurinol, a "suicide" inhibitor of xanthine oxidase. Instead of urate, the final products of purine catabolism are then hypoxanthine and xanthine, which are more soluble and thus more easily excreted into the urine. Allopurinol is oxidized by xanthine oxidase to 2-hydroxyallopurinol (alloxanthine) that remains bound to the molybdenum atom of the enzyme, thereby inactivating it. Allopurinol

  15. Hypouricaemia • decrease in the purine synthesis – e.g. in acute liver disorders, • decrease in the activity of xanthine dehydrogenase – xanthinuria, • – allopurinol therapy • decreased tubular urate reabsorption – some tubular defects, • – inherited renal hypouricaemia, • – uricosurics - probenecid, ketazon and other NSAD

  16. Purine content in foodstuffs Purines in mg per 100 g of edible fraction Fish Cereals and pastry Meat, poultry calves thymus 400 (pickled) herring 790 oat flakes 30 spleen 104 salted anchovy 540 wholemeal bread 14 liver 95 sardine 120 white bread, rolls 8 kidneys 80 carp, trout 55 flour 0 horse meat 80 pike 48 Vegetables tongue 55 salmon 22 potatoes 6 veal, pork 48 peasecod 80 Milk, eggs beef 40 egg-yolk 5 lentils 70 ham 24 white of an egg 1 peas, beans 45 chicken 40 eggs 2 spinach 23 little pigeons 80 milk 1 10 cauliflower, celery

More Related